Publications by authors named "M Hefer"
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is becoming more prominent globally due to an increase in the prevalence of obesity, dyslipidemia, and type 2 diabetes. A great deal of studies have proposed potential treatments for MASLD, with few of them demonstrating promising results. The aim of this study was to investigate the potential effects of (-)-epicatechin (EPI) on the development of MASLD in an in vitro model using the HepG2 cell line by determining the metabolic viability of the cells and the levels of PPARα, PPARγ, and GSH.
View Article and Find Full Text PDFArticle Synopsis
- Approximately one billion people are affected by metabolic-associated fatty liver disease (MAFLD), a chronic liver condition linked to metabolic issues like obesity and type 2 diabetes, which can lead to severe liver complications with minimal treatment options.
- The successful treatment for MAFLD requires a drug that reduces liver fat, inflammation, and fibrosis, with a focus on improving liver tissue health, but currently, only a few drugs like Saroglitazar have been approved in limited regions.
- Recent advancements show that research efforts are ramping up, with several promising drug candidates nearing approval, including Rezdiffra™, which received accelerated approval in the U.S. for treating MAFLD this year.
Liver fibrosis represents one of the greatest challenges in medicine. The fact that it develops with the progression of numerous diseases with high prevalence (NAFLD, viral hepatitis, etc.) makes liver fibrosis an even greater global health problem.
View Article and Find Full Text PDF[Apropos of acute changes in left ventricular filling induced by antihypertensive treatment].
Arch Mal Coeur Vaiss
August 1992
The purpose of the study was to interpret the acute improvement in left ventricular (LV) filling induced by a new calcium channel blocker (SR 33 557) using Doppler echocardiography. Thirteen patients, 29 to 68 years old (mean 52) with mild to moderate hypertension were examined by Doppler echocardiography before and 4 hours after treatment (SR 33 557: 300 mg). The LV filling parameters, E, A, A/E, VTIM, VTIA, VTIA/VTIM, pressure half time (PHT) and isovolumic relaxation time (IRT) were measured.
View Article and Find Full Text PDF